STEM CELL THERAPEUTIC

MEDIPOST Completes Phase 2a Clinical Trial of NEUROSTEM for Alzheimer’s Disease

MEDIPOST’s Clinical Trial of Next-Generation Cell Therapy Product ‘SMUP-IA-01’ Makes Solid Progress

MEDIPOST Completes Phase 2a Clinical Trial of NEUROSTEM for Alzheimer’s Disease

MEDIPOST Clears Phase II Clinical Trial Approval for CARTISTEM in Japan

MEDIPOST Receives Approval for Phase III Clinical Trial of CARTISTEM for the Treatment of Osteochondral Cartilage Defects in Ankle Joint

MEDIPOST to Expand the GMP facility to increase manufacturing capacity for CARTISTEM and new pipeline of products

MEDIPOST Registers the Chinese Patent for a Mesenchymal Stem Cell Culture Method

MEDIPOST Treats First Patient with Injectable Cell Therapeutic for Knee Osteoarthritis

MEDIPOST’s PNEUMOSTEM Receives Fast Track Designation from the US FDA

MEDIPOST Registers European Patent for the Mesenchymal Stem Cell Culture Method

MEDIPOST Registers the Canadian Patent for a Mesenchymal Stem Cell Culture Method

MEDIPOST’s Injectable Cell Therapeutic for Knee Osteoarthritis Receives Phase 1 Clinical Trial Approval